Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: Two decades of experience at Chang Gung Memorial Hospital

Table 4 Univariate analysis of factors influencing the overall survival of the 312 PCC patients.

Factors	Survival time (mo)				P
	Median	mean	3-yr (%)	5-yr (%)
Gender
Male (n = 128)	7.79	14.66	11.78	2.27
Female (n = 184)	6.84	18.41	10.88	8.61	0.941
Age (yr)
≤58 (n = 163)	6.21	17.07	11.69	6.86
>58 (n = 149)	8.35	17.15	10.7	6.05	0.471
Symptoms
Positive (n = 303)	6.9	16.58	10.75	6
Negative (n = 9)	20.45	41.67	30.48	30.48	0.024
Physical examination
Positive (n = 222)	6.64	15.7	8.08	4.54
Negative (n = 90)	9.67	20.55	20.46	13.56	0.053
AST (IU/L)
≤34 (n = 121)	7.89	15.69	11.56	5.51
>34 (n = 161)	7.30	18.85	12.02	7.28	0.936
ALT (IU/L)
≤36 (n = 139)	7.33	14.94	9.26	5.15
>36 (n = 107)	8.35	21.38	15.12	9.3	0.326
ALP (IU/L)
≤94 (n = 63)	10.39	16.31	12.12	3.64
>94 (n = 214)	6.64	17.22	10.75	6.46	0.2143
Serum CEA (ng/dL)
>5 (n = 70)	4.57	9.58	1.99	1.99
≤5 (n = 103)	10.39	23.17	17.96	9.95	0.0001
Serum CA 19-9 (ng/dL)
>37 (n = 76)	7.4	11.93	10.27	N.A.
≤37 (n = 29)	13.28	25.49	23.76	15.84	0.008
Associated with biliary stones
With biliary stones (n = 186)	6.94	17.86	11.96	7.18
Without biliary stones (n = 126) 7.40	16.50	9.77	5.86	0.693
Type of operation
Hepatectomy (n = 157)	12.99	25.31	17.88	10.15
Non-hepatectomy (n = 155)	3.65	9.03	4.42	2.76	<0.0001

AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; CEA: carcinoembryonal antigen; CA 19-9: carbohydrate antigen; IU: international unit.